Marc Elia
Vorsitzender bei INVIVYD, INC.
Vermögen: - $ am 31.03.2024
Aktive Positionen von Marc Elia
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SQZ BIOTECHNOLOGIES COMPANY | Direktor/Vorstandsmitglied | 09.08.2018 | - |
Independent Dir/Board Member | 09.08.2018 | - | |
FRACTYL HEALTH, INC. | Direktor/Vorstandsmitglied | 16.06.2021 | - |
Independent Dir/Board Member | 16.06.2021 | - | |
INVIVYD, INC. | Independent Dir/Board Member | 22.06.2022 | - |
Vorsitzender | 01.07.2022 | - | |
Direktor/Vorstandsmitglied | 22.06.2022 | 01.07.2022 | |
M28 Capital Management LP
M28 Capital Management LP Investment ManagersFinance M28 Capital Management LP (M28 Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Stamford, Connecticut. The firm was founded by Marc Elia in 2019. M28 Capital provides investment advisory services on a discretionary basis to several private fund clients. | Gründer | 01.08.2012 | - |
Karriereverlauf von Marc Elia
Ehemalige bekannte Positionen von Marc Elia
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Bridger Management LLC
Bridger Management LLC Investment ManagersFinance Bridger Management LLC (Bridger) is a registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Roberto Mignone in 2000 and is a direct subsidiary of Bridger Management II LP. Bridger serves as the investment adviser, with discretionary trading authority, to private, pooled investment vehicles, the securities of which are offered through a private placement memorandum to accredited investors. | Analyst-Equity | 01.01.2012 | 01.09.2019 |
Bridger Capital LLC | Corporate Officer/Principal | 01.01.2012 | 01.09.2019 |
Adimab LLC
Adimab LLC BiotechnologyHealth Technology Adimab LLC provides human therapeutic antibodies. The firm has discovered antibodies for a wide variety of therapeutic targets within many disease areas, including oncology, immunomodulation, inflammation, neuroscience and pain, cardiovascular and metabolic disease and infectious disease. The company was founded in 2007 by Tillman Gerngross, Dane Wittrup and Errik Anderson and is headquartered in Lebanon, NH. | Direktor/Vorstandsmitglied | - | - |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Gründer | 01.01.2007 | - |
Ausbildung von Marc Elia
Carleton College | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 10 |
Operativ
Director/Board Member | 4 |
Independent Dir/Board Member | 3 |
Founder | 2 |
Sektoral
Health Technology | 6 |
Finance | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
FRACTYL HEALTH, INC. | Health Technology |
INVIVYD, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Bridger Management LLC
Bridger Management LLC Investment ManagersFinance Bridger Management LLC (Bridger) is a registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Roberto Mignone in 2000 and is a direct subsidiary of Bridger Management II LP. Bridger serves as the investment adviser, with discretionary trading authority, to private, pooled investment vehicles, the securities of which are offered through a private placement memorandum to accredited investors. | Finance |
Adimab LLC
Adimab LLC BiotechnologyHealth Technology Adimab LLC provides human therapeutic antibodies. The firm has discovered antibodies for a wide variety of therapeutic targets within many disease areas, including oncology, immunomodulation, inflammation, neuroscience and pain, cardiovascular and metabolic disease and infectious disease. The company was founded in 2007 by Tillman Gerngross, Dane Wittrup and Errik Anderson and is headquartered in Lebanon, NH. | Health Technology |
Bridger Capital LLC | |
M28 Capital Management LP
M28 Capital Management LP Investment ManagersFinance M28 Capital Management LP (M28 Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Stamford, Connecticut. The firm was founded by Marc Elia in 2019. M28 Capital provides investment advisory services on a discretionary basis to several private fund clients. | Finance |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Health Technology |